US Patents for PCT: WO2015/101791
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19DELETIONS OR EXON 21 L858R MUTATIONS | |||
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY | |||
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS | |||
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
